ZUMA-24NCT05459571
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 30 versions: 23 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 12, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 20 words
- Primary endpoints: 1 to 2
- Secondary endpoints: 25 to 32
- Publications: details revised at 1 of 1 entry
- Study description shortened, about 1 word
- Minor Trial status: Active, Not Recruiting to Completed
- Enrollment target: estimated 30 to confirmed 35
- Primary and study completion dates changed from estimate of Dec 2025 to Nov 24, 2025
- Notable Primary completion date: Sep 20, 2024 to Dec 2025
- Study completion date: Mar 2026 to Dec 2025
- Minor Primary completion date changed from estimate of Mar 2026 to Sep 20, 2024v27
- Minor Enrollment target: 35 to 30
- Secondary endpoints: 24 to 25
Show 17 earlier versionsHide 17 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: 30 to 35
- Study sites: 17 to 16
- Minor Enrollment target: 40 to 30v19
- Minor Study sites: 16 to 17v18
- Notable Eligibility criteria shortened, about 5 wordsv17
- Minor Study sites: 12 to 16v16
- Minor Site details revised at 1 of 12 sitesv15
- Minor Study sites: 11 to 12v14
- Minor Start date: Aug 10, 2022 to Aug 9, 2022v13
- Minor Study sites: 10 to 11v12
- Minor Study sites: 9 to 10v11
- Minor Study sites: 6 to 9v10
- Minor Study sites: 5 to 6v9
- Minor Study sites revised (5)v7
- Minor Study sites: 3 to 5v6
- Minor Study sites: 2 to 3v5
- Minor Study sites: 1 to 2
- Start date changed from estimate of Aug 2022 to Aug 10, 2022
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (32)
Show 27 moreShow less
Arms and interventions
Participants will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m\^2/day and fludarabine 30 mg/m\^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2. Participants will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10\^6 cells/kg.
Biologicals: Axicabtagene Ciloleucel
Drugs: Cyclophosphamide, Fludarabine, Dexamethasone
Sites
16 sites in 1 country